CohanSLLucassenEBRombaMC, et al. Daclizumab: Mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis. Biomedicines2019; 7(1): E18.
2.
BaldassariLERoseJW. Daclizumab: Development, clinical trials, and practical aspects of use in multiple sclerosis. Neurotherapeutics2017; 14(4): 842–858.
3.
GiovannoniGKapposLGoldR, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord2016; 9: 36–46.
4.
European Medicines Agency. Multiple sclerosis medicine Zinbryta suspended in the EU. Report No. EMA/155367/2018, 8March2018. London: European Medicines Agency.
5.
LuessiFEngelSSpreerA, et al. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm2018; 5(5): e481.
6.
European Medicines Agency. EMA Review of Zinbryta Confirms Medicine’s Risks Outweigh Its Benefits. Report No. EMA/286850/2018, 18 May 2018. London: European Medicines Agency.
7.
StorkLBruckWvonGottbergP, et al. Severe Meningo-/Encephalitis after daclizumab therapy for multiple sclerosis. Mult Scler2019; 25: 1618–1632.
8.
AvasaralaJ. DRESS SYndrome and Daclizumab Failure – Were Potentially Dangerous Signs Missed in Clinical Trial?Drug Target Insights2018; 12: 1–2.
9.
GrossCCSchulte-MecklenbeckARünziA, et al. Impaired NK-mediated regulation of T-cells activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci2016; 113(21): E2973–E2982.
10.
DanikowskiKMJayaraman PrabhakarBS. Regulatory T Cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation2017; 14(1): 117–132.
